Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000150
Chunk: 2

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 2
---
 at a similar level to the original forecast due to an increase of non-deductible expenses mainly from impairments as well as derecognition of deferred tax assets, resulting in an assumed effective tax rate of approximately 37%.

Reported EPS is expected to be JPY 97.14, a decrease of JPY 47.66, or 32.9%, and Core EPS is expected to be JPY 479, a decrease of JPY 6, or 1.2%.

3. Management Guidance for the Fiscal Year Ending March 31, 2026

Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2026 (FY2025) has been revised from the management guidance announced on May 8, 2025.

| CER % Change          |     | Original Management Guidance 
 (May 8, 2025)                |     | Revised Management Guidance 
 (October 30, 2025)          |
|:----------------------|:----|:-----------------------------|:----|:----------------------------|
| Core revenue          |     | Broadly Flat                 |     | Broadly Flat                |
| Core operating profit |     | Broadly Flat                 |     | Low-single-digit % decline  |
| Core EPS              |     | Broadly Flat                 |     | Low-single-digit % decline  |

#### About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

#### Contacts
| Investor Relations             
 Christopher O’Reilly           
 christopher.oreilly@takeda.com 
 +81 (0) 90-6481-3412           |     | Media Relations